Background To assess the anatomical and functional outcomes in eyes with persistent diabetic macular oedema (pDME) on chronic anti-vascular endothelial growth factor therapy switched to intravitreal faricimab. Methods Patients with pDME on chronic anti-vascular endothelial growth factor therapy that were switched to faricimab and received at least three injections at our institution between April 2022 and May 2023 were included in this study. Patients were excluded if they had complete response to previous treatment but were switched to extend treatment intervals if they had steroid or laser treatment for DME within 6 months prior to switch. Clinical and imaging data were extracted from the electronic medical record. Central foveal thickness (CFT) and Snellen visual acuity (VA) were obtained before and after three intravitreal faricimab injections. Generalised estimating equations were used to analyse the change in CFT and VA. Result During the study period, 69 eyes of 53 patients met inclusion criteria. The mean age was 68.6±9.0 years. The mean number of injections prior to switch was 18.1±16.0. Pre-switch mean logarithm of the minimal angle of resolution VA was 0.40±0.30 (Snellen equivalent 20/50) and 0.38±0.27 (Snellen equivalent 20/48) after three faricimab injections (p=0.397). Mean CFT improved from 380±155 microns to 323±147 microns (p<0.001). No ophthalmic or systemic adverse events occurred during the study period. Conclusions Intravitreal faricimab can improve anatomic outcomes while maintaining visual acuity in eyes with pDME previously treated with anti-VEGF therapy. Data are available upon reasonable request.

中文翻译：

---

既往针对持续性糖尿病黄斑水肿进行抗血管内皮生长因子治疗后转用法里昔单抗


背景 为了评估患有持续性糖尿病黄斑水肿 (pDME) 的眼睛在慢性抗血管内皮生长因子治疗转为玻璃体内注射法里西单抗 (faricimab) 后的解剖学和功能结果。方法本研究纳入长期接受抗血管内皮生长因子治疗的 pDME 患者，转用法瑞昔单抗并于 2022 年 4 月至 2023 年 5 月期间在我们机构接受至少 3 次注射。如果患者对之前的治疗有完全反应，则被排除在外，但如果在转换前 6 个月内接受过类固醇或激光治疗 DME，则转换为延长治疗间隔。从电子病历中提取临床和影像数据。在玻璃体内注射 3 次法里昔单抗之前和之后获得中央凹厚度 (CFT) 和 Snellen 视力 (VA)。使用广义估计方程来分析CFT和VA的变化。结果 研究期间，53 名患者的 69 只眼睛符合纳入标准。平均年龄为68.6±9.0岁。转换前的平均注射次数为 18.1±16.0。注射三次法瑞昔单抗后，切换前最小分辨率 VA 角的平均对数为 0.40±0.30（Snellen 等效值 20/50）和 0.38±0.27（Snellen 等效值 20/48）（p=0.397）。平均 CFT 从 380±155 微米提高到 323±147 微米 (p<0.001)。研究期间没有发生眼科或全身不良事件。结论 玻璃体内注射 Faricimab 可以改善先前接受抗 VEGF 治疗的 pDME 眼的解剖结果，同时保持视力。数据可根据合理要求提供。